Imlifidase

N/A

Report date: 2026/05/20 20:02:01

Base Information

Drug NameImlifidase
Drug Alias NameIdeSHMed-IdeSIgG-degrading enzyme of Streptococcus pyogenesStreptococcal cysteine proteinaseIgG-endopeptidase +[7] 
ClassificationBiologics > Protein drugs > Recombinant protein > Fusion proteinBiologics > Protein drugs > Enzyme > Recombinant enzymeBiologics > Protein drugs > Recombinant protein > Recombinant enzyme
Mechanisms of ActionImmunoglobulin G inhibitorsImmunosuppressants
TargetsImmunoglobulin G
Therapy Area/IndicationsRejection of organ transplantationRejection of renal transplantationPurpura, Thrombotic Thrombocytopenic +[7] 
Global Approved IndicationsRejection of renal transplantation
Approved Indications in ChinaN/A
Original Approved Country/TerritoryEU
Original Approved Date2020/08/25
Country/TerritoryCzechiaBelgiumUnited States +[15] 
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaN/A
Originator CompaniesHansamed Inc
China Registration ClassN/A

Develop Information

Active CompaniesMedison PharmaAskBio IncSarepta Therapeutics Inc +[7] 
Inactive CompaniesN/A
Active IndicationsRejection of organ transplantationRejection of renal transplantationGuillain-Barre Syndrome
Inactive IndicationsPurpura, Thrombotic ThrombocytopenicKidney Failure, ChronicRenal Insufficiency, Chronic +[4] 

Other Information

ATC CodeL04AA41
Related LinksN/A